Monoamine oxidase and dementia

Treatment with an inhibitor of MAO-B activity

Alessandro Agnoli, Nicola Martucci, Giovanni Fabbrini, Ann E. Buckley, Mario Fioravanti

Research output: Contribution to journalArticle

32 Citations (Scopus)

Abstract

Patients suffering from Alzheimer type dementia have demonstrated an increase in MAO-B activity. Treatment of these patients with an inhibitor of the monoamine oxidase activity, such as L-Deprenyl (LD), might therefore provide a valid therapeutic intervention. The efficacy of LD was examined in a double-blind, drug versus placebo (PL) study on 20 patients diagnosed between stages 3 and 5 of primary degenerative dementia. Treatment duration was 90 days (5 mg twice a day). All patients underwent clinical, behavioral, and memory evaluations every 30 days. Subjects in the LD group demonstrated an improvement on both attention and memory measures; some of the changes were apparent after only 30 days of treatment. PL patients showed no such improvement and also evidenced a decrease in behavior efficiency during the experimental period. Two patients dropped out of the study, 1 from each treatment group. No differences were found in either the type and number of concomitant treatments or side effects between groups.

Original languageEnglish
Pages (from-to)109-114
Number of pages6
JournalDementia and Geriatric Cognitive Disorders
Volume1
Issue number2
DOIs
Publication statusPublished - 1990

Fingerprint

Monoamine Oxidase
Dementia
Selegiline
Therapeutics
Placebos
Monoamine Oxidase Inhibitors
Alzheimer Disease
Efficiency
Pharmaceutical Preparations

Keywords

  • Attention
  • Dat
  • L-deprenyl
  • Memory

ASJC Scopus subject areas

  • Geriatrics and Gerontology
  • Psychiatry and Mental health
  • Cognitive Neuroscience

Cite this

Monoamine oxidase and dementia : Treatment with an inhibitor of MAO-B activity. / Agnoli, Alessandro; Martucci, Nicola; Fabbrini, Giovanni; Buckley, Ann E.; Fioravanti, Mario.

In: Dementia and Geriatric Cognitive Disorders, Vol. 1, No. 2, 1990, p. 109-114.

Research output: Contribution to journalArticle

Agnoli, Alessandro ; Martucci, Nicola ; Fabbrini, Giovanni ; Buckley, Ann E. ; Fioravanti, Mario. / Monoamine oxidase and dementia : Treatment with an inhibitor of MAO-B activity. In: Dementia and Geriatric Cognitive Disorders. 1990 ; Vol. 1, No. 2. pp. 109-114.
@article{708ab576d8f541f98f4068e3558ab45d,
title = "Monoamine oxidase and dementia: Treatment with an inhibitor of MAO-B activity",
abstract = "Patients suffering from Alzheimer type dementia have demonstrated an increase in MAO-B activity. Treatment of these patients with an inhibitor of the monoamine oxidase activity, such as L-Deprenyl (LD), might therefore provide a valid therapeutic intervention. The efficacy of LD was examined in a double-blind, drug versus placebo (PL) study on 20 patients diagnosed between stages 3 and 5 of primary degenerative dementia. Treatment duration was 90 days (5 mg twice a day). All patients underwent clinical, behavioral, and memory evaluations every 30 days. Subjects in the LD group demonstrated an improvement on both attention and memory measures; some of the changes were apparent after only 30 days of treatment. PL patients showed no such improvement and also evidenced a decrease in behavior efficiency during the experimental period. Two patients dropped out of the study, 1 from each treatment group. No differences were found in either the type and number of concomitant treatments or side effects between groups.",
keywords = "Attention, Dat, L-deprenyl, Memory",
author = "Alessandro Agnoli and Nicola Martucci and Giovanni Fabbrini and Buckley, {Ann E.} and Mario Fioravanti",
year = "1990",
doi = "10.1159/000107128",
language = "English",
volume = "1",
pages = "109--114",
journal = "Dementia and Geriatric Cognitive Disorders",
issn = "1420-8008",
publisher = "S. Karger AG",
number = "2",

}

TY - JOUR

T1 - Monoamine oxidase and dementia

T2 - Treatment with an inhibitor of MAO-B activity

AU - Agnoli, Alessandro

AU - Martucci, Nicola

AU - Fabbrini, Giovanni

AU - Buckley, Ann E.

AU - Fioravanti, Mario

PY - 1990

Y1 - 1990

N2 - Patients suffering from Alzheimer type dementia have demonstrated an increase in MAO-B activity. Treatment of these patients with an inhibitor of the monoamine oxidase activity, such as L-Deprenyl (LD), might therefore provide a valid therapeutic intervention. The efficacy of LD was examined in a double-blind, drug versus placebo (PL) study on 20 patients diagnosed between stages 3 and 5 of primary degenerative dementia. Treatment duration was 90 days (5 mg twice a day). All patients underwent clinical, behavioral, and memory evaluations every 30 days. Subjects in the LD group demonstrated an improvement on both attention and memory measures; some of the changes were apparent after only 30 days of treatment. PL patients showed no such improvement and also evidenced a decrease in behavior efficiency during the experimental period. Two patients dropped out of the study, 1 from each treatment group. No differences were found in either the type and number of concomitant treatments or side effects between groups.

AB - Patients suffering from Alzheimer type dementia have demonstrated an increase in MAO-B activity. Treatment of these patients with an inhibitor of the monoamine oxidase activity, such as L-Deprenyl (LD), might therefore provide a valid therapeutic intervention. The efficacy of LD was examined in a double-blind, drug versus placebo (PL) study on 20 patients diagnosed between stages 3 and 5 of primary degenerative dementia. Treatment duration was 90 days (5 mg twice a day). All patients underwent clinical, behavioral, and memory evaluations every 30 days. Subjects in the LD group demonstrated an improvement on both attention and memory measures; some of the changes were apparent after only 30 days of treatment. PL patients showed no such improvement and also evidenced a decrease in behavior efficiency during the experimental period. Two patients dropped out of the study, 1 from each treatment group. No differences were found in either the type and number of concomitant treatments or side effects between groups.

KW - Attention

KW - Dat

KW - L-deprenyl

KW - Memory

UR - http://www.scopus.com/inward/record.url?scp=0025143661&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025143661&partnerID=8YFLogxK

U2 - 10.1159/000107128

DO - 10.1159/000107128

M3 - Article

VL - 1

SP - 109

EP - 114

JO - Dementia and Geriatric Cognitive Disorders

JF - Dementia and Geriatric Cognitive Disorders

SN - 1420-8008

IS - 2

ER -